Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03565835 · ClinicalTrials.gov registry record · Phase 2
Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer
A Phase 2 study, sponsored by Montefiore Medical Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT03565835 is a Phase 2 study that has completed, run by Montefiore Medical Center. The registered enrollment target is 31 participants.
The verdict
NCT03565835, a Phase 2 study, has completed, sponsored by Montefiore Medical Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The goal of this study is to find out if patients with prostate cancer being treated with the medications abiraterone and prednisone can discontinue hormone injections (examples include leuprolide, goserelin, triptorelin and degarelix). Abiraterone and prednisone are pills used to treat patients with prostate cancer. When abiraterone and prednisone are used, hormone injections are usually continued to maintain a low testosterone level in the blood. This study is being done to find out if testosterone in the blood will stay low while abiraterone and prednisone are used without continued hormone injections.
Interventions
- DRUG Prednisone
- DRUG Abiraterone Acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2018-06-13 |
| Est. Completion | 2021-11-17 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03565835
The ClinicalTrials.gov registry entry for NCT03565835 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Montefiore Medical Center, which has 345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prednisone is the first listed.
NCT03565835 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03565835 about?
NCT03565835 is a clinical study titled "Abiraterone With Discontinuation of Gonadotropin-Releasing Hormone Analogues in Metastatic Prostate Cancer". The goal of this study is to find out if patients with prostate cancer being treated with the medications abiraterone and prednisone can discontinue hormone injections (examples include leuprolide, goserelin, triptorelin and degarelix). Abiraterone and prednisone are pills used to treat patients wit...
What is the current status of trial NCT03565835?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2018-06-13. Estimated completion is 2021-11-17.
What interventions are being tested in trial NCT03565835?
The interventions under investigation include: Prednisone (DRUG), Abiraterone Acetate (DRUG).
Who is sponsoring clinical trial NCT03565835?
This trial is sponsored by Montefiore Medical Center, which has 345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.